Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Magí Farré:

Cannabinoids: from pot to lab. Papaseit E et al. Int J Med Sci. (2018)

Drug Interactions With New Synthetic Opioids. Pérez-Mañá C et al. Front Pharmacol. (2018)

Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines. Arellano AL et al. CNS Neurol Disord Drug Targets. (2017)

Search results

Items: 1 to 20 of 213

1.

Quality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases: A 12-Month Longitudinal Study.

Bouso JC, Jiménez-Garrido D, Ona G, Woźnica D, Dos Santos RG, Hallak JEC, Paranhos BAPB, de Almeida Mendes F, Yonamine M, Alcázar-Córcoles MÁ, Farré M.

Phytother Res. 2020 Feb 21. doi: 10.1002/ptr.6639. [Epub ahead of print]

PMID:
32083789
2.

Mephedrone and Alcohol Interactions in Humans.

Papaseit E, Pérez-Mañá C, de Sousa Fernandes Perna EB, Olesti E, Mateus J, Kuypers KP, Theunissen EL, Fonseca F, Torrens M, Ramaekers JG, de la Torre R, Farré M.

Front Pharmacol. 2020 Jan 28;10:1588. doi: 10.3389/fphar.2019.01588. eCollection 2019.

3.

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials.

Fuentes JJ, Fonseca F, Elices M, Farré M, Torrens M.

Front Psychiatry. 2020 Jan 21;10:943. doi: 10.3389/fpsyt.2019.00943. eCollection 2019.

4.

LC-MS/MS method for the quantification of new psychoactive substances and evaluation of their urinary detection in humans for doping control analysis.

Olesti E, Pascual JA, Ventura M, Papaseit E, Farré M, de la Torre R, Pozo OJ.

Drug Test Anal. 2020 Jan 16. doi: 10.1002/dta.2768. [Epub ahead of print]

PMID:
31950617
5.

Therapeutic potential of ayahuasca in grief: a prospective, observational study.

González D, Cantillo J, Pérez I, Farré M, Feilding A, Obiols JE, Bouso JC.

Psychopharmacology (Berl). 2020 Jan 14. doi: 10.1007/s00213-019-05446-2. [Epub ahead of print]

PMID:
31938878
6.

Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity.

Rodríguez-Morató J, Goday A, Langohr K, Pujadas M, Civit E, Pérez-Mañá C, Papaseit E, Ramon JM, Benaiges D, Castañer O, Farré M, de la Torre R.

Sci Rep. 2019 Dec 31;9(1):20405. doi: 10.1038/s41598-019-57002-9.

7.

Fast and sensitive UHPLC-MS/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual.

Pichini S, Mannocchi G, Gottardi M, Pérez-Acevedo AP, Poyatos L, Papaseit E, Pérez-Mañá C, Farré M, Pacifici R, Busardò FP.

Talanta. 2020 Mar 1;209:120537. doi: 10.1016/j.talanta.2019.120537. Epub 2019 Nov 15.

PMID:
31892011
8.

Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.

Mensen VT, Vreeker A, Nordgren J, Atkinson A, de la Torre R, Farré M, Ramaekers JG, Brunt TM.

Psychopharmacology (Berl). 2019 Sep;236(9):2677-2685. doi: 10.1007/s00213-019-05238-8. Epub 2019 Apr 9.

9.

A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.

de la Torre R, de Sola S, Farré M, Xicota L, Cuenca-Royo A, Rodriguez J, León A, Langohr K, Gomis-González M, Hernandez G, Esteba S, Del Hoyo L, Sánchez-Gutiérrez J, Cortés MJ, Ozaita A, Espadaler JM, Novell R, Martínez-Leal R, Milá M, Dierssen M; TESXF Study Group.

Clin Nutr. 2020 Feb;39(2):378-387. doi: 10.1016/j.clnu.2019.02.028. Epub 2019 Mar 25.

PMID:
30962103
10.

Soy Isoflavone Extract Does Not Increase the Intoxicating Effects of Acute Alcohol Ingestion in Human Volunteers.

Martínez-Riera R, Pérez-Mañá C, Papaseit E, Fonseca F, de la Torre R, Pizarro N, Torrens M, Farré M.

Front Pharmacol. 2019 Feb 27;10:131. doi: 10.3389/fphar.2019.00131. eCollection 2019.

11.

Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders.

García-Marchena N, Barrera M, Mestre-Pintó JI, Araos P, Serrano A, Pérez-Mañá C, Papaseit E, Fonseca F, Ruiz JJ, Rodríguez de Fonseca F, Farré M, Pavón FJ, Torrens M.

PLoS One. 2019 Mar 14;14(3):e0213791. doi: 10.1371/journal.pone.0213791. eCollection 2019.

12.

Dose-Response Pharmacological Study of Mephedrone and Its Metabolites: Pharmacokinetics, Serotoninergic Effects, and Impact of CYP2D6 Genetic Variation.

Olesti E, Farré M, Carbó ML, Papaseit E, Perez-Mañá C, Torrens M, Yubero-Lahoz S, Pujadas M, Pozo ÓJ, de la Torre R.

Clin Pharmacol Ther. 2019 Sep;106(3):596-604. doi: 10.1002/cpt.1417. Epub 2019 Apr 8.

PMID:
30815856
13.

Reversible taste and smell dysfunction associated with sodium valproate and quetiapine in bipolar depression: a case report.

Alvarez P, Papaseit E, Pérez V, Bulbena A, Farré M.

Actas Esp Psiquiatr. 2019 Jan;47(1):33-6. Epub 2019 Jan 1. No abstract available.

14.

Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis.

Torres-Moreno MC, Papaseit E, Torrens M, Farré M.

JAMA Netw Open. 2018 Oct 5;1(6):e183485. doi: 10.1001/jamanetworkopen.2018.3485.

15.

Metabolomics predicts the pharmacological profile of new psychoactive substances.

Olesti E, De Toma I, Ramaekers JG, Brunt TM, Carbó ML, Fernández-Avilés C, Robledo P, Farré M, Dierssen M, Pozo ÓJ, de la Torre R.

J Psychopharmacol. 2019 Mar;33(3):347-354. doi: 10.1177/0269881118812103. Epub 2018 Nov 19.

PMID:
30451567
16.

Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial.

Salas-Salvadó J, Díaz-López A, Ruiz-Canela M, Basora J, Fitó M, Corella D, Serra-Majem L, Wärnberg J, Romaguera D, Estruch R, Vidal J, Martínez JA, Arós F, Vázquez C, Ros E, Vioque J, López-Miranda J, Bueno-Cavanillas A, Tur JA, Tinahones FJ, Martín V, Lapetra J, Pintó X, Daimiel L, Delgado-Rodríguez M, Matía P, Gómez-Gracia E, Díez-Espino J, Babio N, Castañer O, Sorlí JV, Fiol M, Zulet MÁ, Bulló M, Goday A, Martínez-González MÁ; PREDIMED-Plus investigators.

Diabetes Care. 2019 May;42(5):777-788. doi: 10.2337/dc18-0836. Epub 2018 Nov 2.

PMID:
30389673
17.

Drug Interactions With New Synthetic Opioids.

Pérez-Mañá C, Papaseit E, Fonseca F, Farré A, Torrens M, Farré M.

Front Pharmacol. 2018 Oct 11;9:1145. doi: 10.3389/fphar.2018.01145. eCollection 2018. Review.

18.

Cannabinoids: from pot to lab.

Papaseit E, Pérez-Mañá C, Pérez-Acevedo AP, Hladun O, Torres-Moreno MC, Muga R, Torrens M, Farré M.

Int J Med Sci. 2018 Aug 6;15(12):1286-1295. doi: 10.7150/ijms.27087. eCollection 2018. Review.

19.

Reply.

Poyatos L, Farré M, López A.

Med Clin (Barc). 2019 Jan 18;152(2):79-80. doi: 10.1016/j.medcli.2018.05.004. Epub 2018 Jun 7. English, Spanish. No abstract available.

PMID:
29887177
20.

Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?

Sanvisens A, Muñoz A, Bolao F, Zuluaga P, Farré M, Jarrin I, Tor J, Muga R.

Drug Alcohol Depend. 2018 Jul 1;188:180-186. doi: 10.1016/j.drugalcdep.2018.04.008. Epub 2018 May 16.

PMID:
29778771

Supplemental Content

Loading ...
Support Center